Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome

K. Nakai, Y. Kanda, S. Fukuhara, H. Sakamaki, Shinichiro Okamoto, Y. Kodera, Ryuji Tanosaki, S. Takahashi, T. Matsushima, Y. Atsuta, N. Hamajima, M. Kasai, S. Kato

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a curative treatment for myelodysplastic syndrome (MDS). The object of this study was to evaluate the impact of chemotherapy before allo-SCT. We analyzed the data of 283 patients who underwent allo-SCT from an HLA-identical sibling donor for MDS that were reported to the Japan Society for Hematopoietic Cell Transplantation. The cumulative incidence of grade II-IV acute GVHD was 33%. Overall survival (OS) at 5 and 10 years was 48.8 and 42.5%, respectively. Multivariate analyses identified karyotype, FAB classification, and the history of chemotherapy before allo-SCT as significant predictors for OS. OS at 5 years was 57% for patients who underwent allo-SCT as a primary treatment for refractory anemia with excess blasts in transformation (RAEB-t) or secondary acute myeloid leukemia (AML) and 54% for those who underwent allo-SCT in remission after induction chemotherapy (P = 0.81). The proportion of patients with a poor karyotype was equivalent between the two groups (P = 0.44). Although only a randomized controlled trial will be able to establish a definite conclusion, these results do not support the administration of induction chemotherapy for patients with RAEB-t or secondary AML before allo-SCT.

Original languageEnglish
Pages (from-to)396-401
Number of pages6
JournalLeukemia
Volume19
Issue number3
DOIs
Publication statusPublished - 2005 Mar

Fingerprint

Hematopoietic Stem Cell Transplantation
Myelodysplastic Syndromes
Siblings
Tissue Donors
Drug Therapy
Refractory Anemia with Excess of Blasts
Induction Chemotherapy
Lymphocyte Activation
Karyotype
Acute Myeloid Leukemia
Survival
Remission Induction
Cell Transplantation
Japan
Multivariate Analysis
Randomized Controlled Trials
History
Incidence
Therapeutics

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • Graft-versus-host disease
  • Myelodysplastic syndrome

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. / Nakai, K.; Kanda, Y.; Fukuhara, S.; Sakamaki, H.; Okamoto, Shinichiro; Kodera, Y.; Tanosaki, Ryuji; Takahashi, S.; Matsushima, T.; Atsuta, Y.; Hamajima, N.; Kasai, M.; Kato, S.

In: Leukemia, Vol. 19, No. 3, 03.2005, p. 396-401.

Research output: Contribution to journalArticle

Nakai, K, Kanda, Y, Fukuhara, S, Sakamaki, H, Okamoto, S, Kodera, Y, Tanosaki, R, Takahashi, S, Matsushima, T, Atsuta, Y, Hamajima, N, Kasai, M & Kato, S 2005, 'Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome', Leukemia, vol. 19, no. 3, pp. 396-401. https://doi.org/10.1038/sj.leu.2403640
Nakai, K. ; Kanda, Y. ; Fukuhara, S. ; Sakamaki, H. ; Okamoto, Shinichiro ; Kodera, Y. ; Tanosaki, Ryuji ; Takahashi, S. ; Matsushima, T. ; Atsuta, Y. ; Hamajima, N. ; Kasai, M. ; Kato, S. / Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. In: Leukemia. 2005 ; Vol. 19, No. 3. pp. 396-401.
@article{979980fc18634fda8b9c3126491a5c43,
title = "Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome",
abstract = "Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a curative treatment for myelodysplastic syndrome (MDS). The object of this study was to evaluate the impact of chemotherapy before allo-SCT. We analyzed the data of 283 patients who underwent allo-SCT from an HLA-identical sibling donor for MDS that were reported to the Japan Society for Hematopoietic Cell Transplantation. The cumulative incidence of grade II-IV acute GVHD was 33{\%}. Overall survival (OS) at 5 and 10 years was 48.8 and 42.5{\%}, respectively. Multivariate analyses identified karyotype, FAB classification, and the history of chemotherapy before allo-SCT as significant predictors for OS. OS at 5 years was 57{\%} for patients who underwent allo-SCT as a primary treatment for refractory anemia with excess blasts in transformation (RAEB-t) or secondary acute myeloid leukemia (AML) and 54{\%} for those who underwent allo-SCT in remission after induction chemotherapy (P = 0.81). The proportion of patients with a poor karyotype was equivalent between the two groups (P = 0.44). Although only a randomized controlled trial will be able to establish a definite conclusion, these results do not support the administration of induction chemotherapy for patients with RAEB-t or secondary AML before allo-SCT.",
keywords = "Allogeneic hematopoietic stem cell transplantation, Graft-versus-host disease, Myelodysplastic syndrome",
author = "K. Nakai and Y. Kanda and S. Fukuhara and H. Sakamaki and Shinichiro Okamoto and Y. Kodera and Ryuji Tanosaki and S. Takahashi and T. Matsushima and Y. Atsuta and N. Hamajima and M. Kasai and S. Kato",
year = "2005",
month = "3",
doi = "10.1038/sj.leu.2403640",
language = "English",
volume = "19",
pages = "396--401",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome

AU - Nakai, K.

AU - Kanda, Y.

AU - Fukuhara, S.

AU - Sakamaki, H.

AU - Okamoto, Shinichiro

AU - Kodera, Y.

AU - Tanosaki, Ryuji

AU - Takahashi, S.

AU - Matsushima, T.

AU - Atsuta, Y.

AU - Hamajima, N.

AU - Kasai, M.

AU - Kato, S.

PY - 2005/3

Y1 - 2005/3

N2 - Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a curative treatment for myelodysplastic syndrome (MDS). The object of this study was to evaluate the impact of chemotherapy before allo-SCT. We analyzed the data of 283 patients who underwent allo-SCT from an HLA-identical sibling donor for MDS that were reported to the Japan Society for Hematopoietic Cell Transplantation. The cumulative incidence of grade II-IV acute GVHD was 33%. Overall survival (OS) at 5 and 10 years was 48.8 and 42.5%, respectively. Multivariate analyses identified karyotype, FAB classification, and the history of chemotherapy before allo-SCT as significant predictors for OS. OS at 5 years was 57% for patients who underwent allo-SCT as a primary treatment for refractory anemia with excess blasts in transformation (RAEB-t) or secondary acute myeloid leukemia (AML) and 54% for those who underwent allo-SCT in remission after induction chemotherapy (P = 0.81). The proportion of patients with a poor karyotype was equivalent between the two groups (P = 0.44). Although only a randomized controlled trial will be able to establish a definite conclusion, these results do not support the administration of induction chemotherapy for patients with RAEB-t or secondary AML before allo-SCT.

AB - Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a curative treatment for myelodysplastic syndrome (MDS). The object of this study was to evaluate the impact of chemotherapy before allo-SCT. We analyzed the data of 283 patients who underwent allo-SCT from an HLA-identical sibling donor for MDS that were reported to the Japan Society for Hematopoietic Cell Transplantation. The cumulative incidence of grade II-IV acute GVHD was 33%. Overall survival (OS) at 5 and 10 years was 48.8 and 42.5%, respectively. Multivariate analyses identified karyotype, FAB classification, and the history of chemotherapy before allo-SCT as significant predictors for OS. OS at 5 years was 57% for patients who underwent allo-SCT as a primary treatment for refractory anemia with excess blasts in transformation (RAEB-t) or secondary acute myeloid leukemia (AML) and 54% for those who underwent allo-SCT in remission after induction chemotherapy (P = 0.81). The proportion of patients with a poor karyotype was equivalent between the two groups (P = 0.44). Although only a randomized controlled trial will be able to establish a definite conclusion, these results do not support the administration of induction chemotherapy for patients with RAEB-t or secondary AML before allo-SCT.

KW - Allogeneic hematopoietic stem cell transplantation

KW - Graft-versus-host disease

KW - Myelodysplastic syndrome

UR - http://www.scopus.com/inward/record.url?scp=20144375580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144375580&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2403640

DO - 10.1038/sj.leu.2403640

M3 - Article

VL - 19

SP - 396

EP - 401

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 3

ER -